VEGFA and neoplasm: In contrast to adenocarcinoma of the lung or colon where mutations in EGFR or K-RAS are the markers clearly predicting the sensitivity of tumor cells to EGFR inhibitors, the presence of VHL mutations is not a clear indication for the use of VEGF/VEGFR inhibitors or other antiangiogenic drugs.